Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Upstream therapy for atrial fibrillation].
Goette A, Hammwöhner M, Bukowska A. Goette A, et al. Herzschrittmacherther Elektrophysiol. 2014 Mar;25(1):33-40. doi: 10.1007/s00399-014-0303-0. Herzschrittmacherther Elektrophysiol. 2014. PMID: 24519662 German.
A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
Lip GY, Merino J, Ezekowitz M, Ellenbogen K, Zamoryakhin D, Lanz H, Jin J, Al-Saadi N, Mercuri M, Goette A. Lip GY, et al. Among authors: goette a. Am Heart J. 2015 May;169(5):597-604.e5. doi: 10.1016/j.ahj.2015.02.009. Epub 2015 Feb 21. Am Heart J. 2015. PMID: 25965706 Free article. Clinical Trial.
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GY; ENSURE-AF investigators. Goette A, et al. Lancet. 2016 Oct 22;388(10055):1995-2003. doi: 10.1016/S0140-6736(16)31474-X. Epub 2016 Aug 30. Lancet. 2016. PMID: 27590218 Clinical Trial.
Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial).
Lip GYH, Al-Saady N, Jin J, Sun M, Melino M, Winters SM, Zamoryakhin D, Goette A. Lip GYH, et al. Among authors: goette a. Am J Cardiol. 2017 Sep 1;120(5):792-796. doi: 10.1016/j.amjcard.2017.06.005. Epub 2017 Jun 15. Am J Cardiol. 2017. PMID: 28709650 Free article. Clinical Trial.
The safety of edoxaban for treating atrial fibrillation.
Hammwöhner M, Goette A. Hammwöhner M, et al. Among authors: goette a. Expert Opin Drug Saf. 2017 Nov;16(11):1295-1303. doi: 10.1080/14740338.2017.1372418. Epub 2017 Sep 18. Expert Opin Drug Saf. 2017. PMID: 28862063 Review.
Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial.
Vranckx P, Lewalter T, Valgimigli M, Tijssen JG, Reimitz PE, Eckardt L, Lanz HJ, Zierhut W, Smolnik R, Goette A. Vranckx P, et al. Among authors: goette a. Am Heart J. 2018 Feb;196:105-112. doi: 10.1016/j.ahj.2017.10.009. Epub 2017 Oct 23. Am Heart J. 2018. PMID: 29421002 Free article. Clinical Trial.
280 results